Lambert-Eaton Myasthenic Syndrome
GPTKB entity
Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
autoimmune disease
muscular dystrophy |
| gptkbp:abbreviation |
gptkb:LEMS
|
| gptkbp:affects |
neuromuscular junction
|
| gptkbp:associatedWith |
Small Cell Lung Cancer
|
| gptkbp:causedBy |
autoantibodies against voltage-gated calcium channels
|
| gptkbp:diagnosedBy |
electromyography
antibody testing |
| gptkbp:differentialDiagnosis |
gptkb:myasthenia_gravis
|
| gptkbp:eponymOf |
gptkb:Lambert
gptkb:Eaton |
| gptkbp:firstDescribed |
gptkb:Lee_Eaton
gptkb:Edward_Lambert 1956 |
| https://www.w3.org/2000/01/rdf-schema#label |
Lambert-Eaton Myasthenic Syndrome
|
| gptkbp:ICD-10_code |
gptkb:G70.3
|
| gptkbp:MeSH_ID |
D008297
|
| gptkbp:OMIM |
606073
|
| gptkbp:prevalence |
rare
|
| gptkbp:symptom |
fatigue
muscle weakness autonomic dysfunction dry mouth difficulty walking |
| gptkbp:treatment |
gptkb:3,4-diaminopyridine
gptkb:pyridostigmine immunosuppressants intravenous immunoglobulin plasmapheresis |
| gptkbp:bfsParent |
gptkb:Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
5
|